{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:21:13Z","timestamp":1762510873510,"version":"build-2065373602"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple eruptive dermatofibromas (MEDFs) are characterized by the rapid development of multiple dermatofibromas within a short period, often associated with underlying immune dysregulation or immunosuppressive therapies. We report a rare case of MEDFs in a young male with refractory psoriasis, who developed multiple cutaneous tumors following sequential treatment with biologic agents: secukinumab, guselkumab, and adalimumab. Despite achieving partial control of psoriasis, the patient experienced the onset of widespread, asymptomatic dermatofibromas, leading to the cessation of biologic therapy. Clinical examination, dermoscopic evaluation, and histopathological analysis confirmed the diagnosis of MEDFs. The Naranjo algorithm and WHO-UMC scale suggested a probable adverse drug reaction as the causative factor. The pathogenesis may involve a Th2-polarizing immune shift and persistent activation of antigen-presenting cells, possibly triggered by the cumulative effects of the biologics used. However, as a single-case report, our findings require validation through larger cohort studies to establish causality and incidence. This case highlights the potential for MEDFs as a novel adverse effect of biologic therapies and underscores the need for awareness and monitoring of such reactions in clinical practice.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1611831","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:17:12Z","timestamp":1762510632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple eruptive dermatofibromas occurred after receiving sequential treatment with secukinumab, guselkumab, and adalimumab: case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Weiquan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linglu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14888","article-title":"Multiple dermatofibromas, associated clinical and histological characteristics: A systematic review","volume":"20","author":"Seifi","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221120818","article-title":"Systemic disease association with multiple eruptive dermatofibromas: A systematic review","volume":"26","author":"Ridha","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05047.x","article-title":"Multiple eruptive plaque-like dermatofibromas during anti-TNF\u03b1 treatment","volume":"52","author":"Caldarola","year":"2013","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/pts.0000000000001213","article-title":"Comparison of WHO-UMC and naranjo scales for causality assessment of reported adverse drug reactions","volume":"20","author":"Pandit","year":"2024","journal-title":"J Patient Saf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2017.17.03.025","article-title":"Multiple clustered dermatofibromas following ustekinumab treatment for psoriasis vulgaris","volume":"17","author":"Ruiz-Villaverde","year":"2017","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5070\/D32112029541","article-title":"Multiple eruptive dermatofibromas","volume":"21","author":"Callahan","year":"2015","journal-title":"Dermatol Online J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000117708","article-title":"Multiple eruptive dermatofibromas in a patient receiving efalizumab","volume":"216","author":"Santos-Juanes","year":"2008","journal-title":"Dermatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s424707","article-title":"Multiple eruptive dermatofibroma: A case report","volume":"17","author":"Yao","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03089.x","article-title":"Dermatofibroma: a possible model of local fibrosis with epithelial\/mesenchymal cell interaction","volume":"23","author":"Yamamoto","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jdermsci.2020.09.002","article-title":"A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis","volume":"101","author":"Liu","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.11.118","article-title":"Interleukin 23 regulates the functions of human decidual immune cells during early pregnancy","volume":"469","author":"Cai","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.27203","article-title":"Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells","volume":"62","author":"Ma","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000246714","article-title":"Dermatofibroma: an abortive immunoreactive process mediated by dermal dendritic cells","volume":"190","author":"Nestle","year":"1995","journal-title":"Dermatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e15814","DOI":"10.1111\/dth.15814","article-title":"New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: The role of systemic treatments as a possible trigger","volume":"35","author":"Paolino","year":"2022","journal-title":"Dermatol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1017938","article-title":"Immunological changes in peripheral blood of ankylosing spondylitis patients during anti-TNF-\u03b1 Therapy and their correlations with treatment outcomes","volume":"2021","author":"Chen","year":"2021","journal-title":"J Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:17:13Z","timestamp":1762510633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2025.1611831"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1611831","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1611831"}}